查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961466

ELISpot 和 FluoroSpot 檢測市場 - 全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、最終用戶、地區和競爭對手分類，2021-2031 年

ELISpot and FluoroSpot Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 ELISpot 和 FluoroSpot 檢測市場預計將從 2025 年的 10.6 億美元成長到 2031 年的 15.1 億美元，複合年成長率為 5.96%。

這些高靈敏度的免疫檢測技術旨在在單細胞層級檢測和定量細胞激素分泌細胞，為免疫監測提供關鍵數據。該市場的主要成長要素是結核病等感染疾病在全球範圍內日益嚴重的負擔以及癌症免疫療法研究的擴展，這兩者都需要對細胞免疫反應進行精確評估。此外，疫苗研發計畫的快速進展也是一個重要的驅動力，推動了臨床試驗中對這些檢測方法的需求。世界衛生組織（WHO）報告稱，2024年全球新增結核病病例約830萬例，凸顯了對干擾素-γ釋放試驗等精準診斷工具的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 10.6億美元
市場規模：2031年 15.1億美元
複合年成長率：2026-2031年 5.96%
成長最快的細分市場 檢測試劑盒
最大的市場 北美洲

儘管市場需求強勁，但先進檢測試劑盒和自動化檢測設備的高成本構成了重大挑戰。此外，這些方法的技術複雜性也加劇了這種經濟障礙，因為數據分析需要專業人員操作，這限制了小規模實驗室和資源匱乏地區採用這些先進技術。因此，這些因素可能會阻礙市場的整體擴張。

市場促進因素

癌症免疫療法和T細胞反應研究的快速進展正在推動全球ELISpot和FluoroSpot檢測市場的發展。這些檢測方法對於監測臨床試驗中的免疫反應至關重要，尤其是在評估CAR-T細胞療法和查核點抑制劑的療效方面。隨著研究人員積極探索新的靶點，對用於定量細胞激素分泌細胞的高靈敏度工具的需求日益成長。越來越多的監管結果要求進行嚴格的免疫監測，進一步推動了這一趨勢。例如，癌症研究所的《2024年影響報告》顯示，僅在過去一年，就有13種新的免疫療法獲得了FDA的核准，這一激增直接凸顯了對精準技術的需求，以支持不斷擴大的開發平臺。

同時，疫苗研發日益受到重視，這成為一股重要的驅動力，也催生了對強大平台的需求，以便能夠測量除簡單抗體反應之外的細胞免疫。向T細胞評估的轉變已使這些檢測方法成為感染疾病疫苗研究的關鍵基準。領先的生物技術公司正在投入大量預算來支持這項創新。正如Moderna公司在其2024年第二季財報新聞稿中所述，該公司預計2024年全年研發支出約為45億美元，這反映出其對利用這些工具的專案投入了大規模資金。此外，整個產業的投資成長也支持了這一發展。根據歐洲製藥工業協會聯合會（EFPIA）的數據，歐洲製藥業預計將在2024年投資550億歐元用於研發，這凸顯了推動這些檢測方法應用的巨額資金投入。

市場挑戰

自動化檢測系統的高成本以及試劑盒的持續投入是全球ELISpot和FluoroSpot檢測市場擴張的主要障礙。小規模的實驗室和診斷機構，尤其是在感染疾病負擔最重的低度開發地區，往往缺乏足夠的資金來部署這些昂貴的平台。這種經濟上的差距迫使許多機構依賴準確度較低的傳統方法，限制了這些先進、高靈敏度技術的潛在市場。

生命科學領域整體資金籌措困難加劇了這個挑戰，直接影響了購買資本設備的能力。根據 MassBio 統計，2025 年上半年生物技術領域的創業投資較去年同期下降超過 17%。資金籌措減少迫使實驗室推遲設備升級，並避免投資昂貴的診斷工具。因此，設備高昂的初始成本加上外部投資的減少，導致市場滲透困難，減緩了這些檢測方法的整體普及速度。

市場趨勢

將人工智慧驅動的演算法整合到自動化斑點分析中，正從根本上改變全球市場數據解讀的基礎。實驗室正擴大採用深度學習模型來標準化斑點計數，從而消除手動顯微鏡檢查中固有的操作者間差異。這種轉變在高通量螢光斑點檢測中尤其關鍵，因為這類檢測需要複雜的計算分解來區分重疊的頻譜訊號。主要產業參與者透過數位轉型獲利，其財務表現也印證了這些數位工具的商業性可行性。根據Revvity公司2025年2月發布的截至2024年12月29日的年度報告，其生命科學部門的軟體收入增加了2,250萬美元，凸顯了客戶對能夠簡化複雜免疫學工作流程的數位分析平台的投資激增。

多重流式點陣技術在多功能免疫分析中的廣泛應用，標誌著其在技術上相較於傳統的單次分析ELISpot方法取得了決定性的進步。研究人員優先考慮能夠同時檢測單一細胞中多種細胞激素的檢測方法，從而能夠詳細表徵T細胞的多功能性，而T細胞是感染疾病和腫瘤研究中重要的保護性指標。這種對高資訊量數據的需求，正推動蛋白質分析工具製造商的持續收入成長。根據Bio-Techne公司於2025年8月發布的2025年第四季財報，其蛋白質科學部門的淨銷售額達到2.265億美元，較去年同期成長6%。這凸顯了市場對多重試劑和檢測平台（多變量免疫分析所必需的）的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球ELISpot與FluoroSpot檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類別（檢測試劑盒、分析儀器、相關產品）
    • 透過應用（診斷、調查）
    • 依最終用戶（醫院/診所、研究機構、生物製藥公司、合約研究組織）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美ELISpot與FluoroSpot檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲ELISpot與FluoroSpot檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區ELISpot與FluoroSpot檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲ELISpot和FluoroSpot偵測的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲ELISpot與FluoroSpot檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球ELISpot與FluoroSpot檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Becton, Dickinson and Company
  • U-CyTech BV
  • Cellular Technology Limited
  • Mabtech AB
  • Abcam Limited
  • AID AUTOIMMUN DIAGNOSTIKA GMBH
  • Mikrogen GmbH
  • Bio-Connect Group
  • Oxford Immunotec USA, Inc.
  • Bio-Techne Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23226

The Global ELISpot and FluoroSpot Assay Market is projected to expand from USD 1.06 billion in 2025 to USD 1.51 billion by 2031, reflecting a compound annual growth rate of 5.96%. These high-sensitivity immunoassay technologies are designed to detect and quantify cytokine-secreting cells at the single-cell level, providing essential data for immunological monitoring. The market is primarily driven by the increasing global burden of infectious diseases, such as tuberculosis, and the growing field of cancer immunotherapy research, both of which require precise evaluation of cellular immune responses. Additionally, the rapid pace of vaccine development programs acts as a significant catalyst, boosting demand for these assays in clinical trials. In 2024, the World Health Organization reported approximately 8.3 million new tuberculosis diagnoses worldwide, underscoring the critical need for accurate diagnostic tools like interferon-gamma release assays.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.06 Billion
Market Size 2031USD 1.51 Billion
CAGR 2026-20315.96%
Fastest Growing SegmentAssay Kits
Largest MarketNorth America

Despite strong market demand, the high cost associated with advanced assay kits and automated detection instruments poses a significant challenge. This financial barrier is often exacerbated by the technical complexity of the methods, which require skilled personnel for data analysis, thereby limiting the adoption of these sophisticated technologies in smaller research laboratories and resource-constrained settings. Consequently, these factors potentially hinder the overall expansion of the market.

Market Driver

The rapid growth of cancer immunotherapy and T-cell response research serves as a primary engine for the Global ELISpot and FluoroSpot Assay Market. These assays have become indispensable for monitoring immune responses in clinical trials, particularly for evaluating the efficacy of CAR-T cell therapies and checkpoint inhibitors. As researchers actively pursue new targets, the need for high-sensitivity tools to quantify cytokine-secreting cells has intensified. This momentum is supported by increasing regulatory achievements that demand rigorous immune monitoring. For instance, the Cancer Research Institute's '2024 Impact Report' noted 13 new FDA approvals for immunotherapy treatments in the past year alone, a surge that directly amplifies the necessity for precise technologies to support these expanding developmental pipelines.

Simultaneously, the intensified focus on vaccine development acts as a critical driver, necessitating robust platforms for measuring cellular immunity beyond simple antibody responses. The shift toward T-cell assessment has positioned these assays as essential benchmarks in infectious disease vaccine research. Major biotechnology firms are maintaining significant budgets to sustain this innovation. As reported in Moderna, Inc.'s 'Second Quarter 2024 Financial Results' press release, the company anticipated full-year 2024 research and development expenses to be approximately $4.5 billion, reflecting massive capital allocation toward programs utilizing these tools. Furthermore, broader sector investment supports this growth; according to the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical industry invested an estimated €55,000 million in R&D in Europe in 2024, highlighting the financial commitment driving assay adoption.

Market Challenge

The high cost of automated detection instruments and the recurring expense of assay kits present a substantial barrier to the expansion of the Global ELISpot and FluoroSpot Assay Market. Smaller research laboratories and diagnostic facilities, particularly in developing regions where infectious disease burdens are highest, often lack the capital budget required to procure these expensive platforms. This financial disparity forces many institutions to continue relying on older, less precise methodologies, thereby restricting the addressable market for these advanced high-sensitivity technologies.

The challenge is further intensified by the tightening of financial resources within the broader life sciences sector, which directly impacts purchasing power for capital equipment. According to MassBio, in 2025, venture capital investment in the biotechnology sector declined by more than 17% during the first half of the year compared to the same period in 2024. This contraction in available funding compels laboratories to defer upgrades and avoid investing in premium diagnostic tools. Consequently, the combination of steep upfront instrument costs and reduced external investment creates a difficult environment for market penetration, slowing the overall adoption of these assays.

Market Trends

The integration of AI-driven algorithms for automated spot analysis is fundamentally reshaping data interpretation within the global market. Laboratories are increasingly deploying deep learning models to standardize spot counting, aiming to eliminate the inter-operator variability inherent in manual microscopy. This shift is particularly critical for high-throughput FluoroSpot assays where differentiating overlapping spectral signals requires advanced computational deconvolution. The commercial viability of these digital tools is evident in the financial performance of key industry players who are monetizing this digital transformation. According to Revvity, Inc., February 2025, in the 'Annual Report for Fiscal Year Ending 12/29, 2024', the company's Life Sciences segment reported an increase of $22.5 million in software revenue, highlighting the surging customer investment in digital analysis platforms that streamline complex immunological workflows.

The widespread adoption of Multiplex FluoroSpot for polyfunctional immune profiling represents a definitive technical evolution over traditional single-analyte ELISpot methods. Researchers are prioritizing assays that can simultaneously detect multiple cytokines from a single cell, allowing for the granular characterization of T-cell polyfunctionality which is a superior correlate of protection in infectious disease and oncology studies. This demand for high-content data is driving sustained revenue growth for manufacturers specializing in protein analysis tools. According to Bio-Techne, August 2025, in the 'Bio-Techne Releases Fourth Quarter Fiscal 2025 Results' press release, the Protein Sciences segment achieved net sales of $226.5 million, an increase of 6% compared to the previous year, underscoring the robust market appetite for multiplex reagents and assay platforms essential for multi-parametric immune monitoring.

Key Market Players

  • Becton, Dickinson and Company
  • U-CyTech BV
  • Cellular Technology Limited
  • Mabtech AB
  • Abcam Limited
  • AID AUTOIMMUN DIAGNOSTIKA GMBH
  • Mikrogen GmbH
  • Bio-Connect Group
  • Oxford Immunotec USA, Inc.
  • Bio-Techne Corporation

Report Scope

In this report, the Global ELISpot and FluoroSpot Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ELISpot and FluoroSpot Assay Market, By Product

  • Assay Kits
  • Analyzers
  • Ancillary Products

ELISpot and FluoroSpot Assay Market, By Application

  • Diagnostic
  • Research

ELISpot and FluoroSpot Assay Market, By End user

  • Hospitals & Clinics
  • Research Institutes
  • Biopharmaceutical Companies
  • CROs

ELISpot and FluoroSpot Assay Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global ELISpot and FluoroSpot Assay Market.

Available Customizations:

Global ELISpot and FluoroSpot Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ELISpot and FluoroSpot Assay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Assay Kits, Analyzers, Ancillary Products)
    • 5.2.2. By Application (Diagnostic, Research)
    • 5.2.3. By End user (Hospitals & Clinics, Research Institutes, Biopharmaceutical Companies, CROs)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America ELISpot and FluoroSpot Assay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States ELISpot and FluoroSpot Assay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada ELISpot and FluoroSpot Assay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico ELISpot and FluoroSpot Assay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End user

7. Europe ELISpot and FluoroSpot Assay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany ELISpot and FluoroSpot Assay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End user
    • 7.3.2. France ELISpot and FluoroSpot Assay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom ELISpot and FluoroSpot Assay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy ELISpot and FluoroSpot Assay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain ELISpot and FluoroSpot Assay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End user

8. Asia Pacific ELISpot and FluoroSpot Assay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China ELISpot and FluoroSpot Assay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End user
    • 8.3.2. India ELISpot and FluoroSpot Assay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan ELISpot and FluoroSpot Assay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea ELISpot and FluoroSpot Assay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia ELISpot and FluoroSpot Assay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End user

9. Middle East & Africa ELISpot and FluoroSpot Assay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia ELISpot and FluoroSpot Assay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE ELISpot and FluoroSpot Assay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa ELISpot and FluoroSpot Assay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End user

10. South America ELISpot and FluoroSpot Assay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil ELISpot and FluoroSpot Assay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia ELISpot and FluoroSpot Assay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina ELISpot and FluoroSpot Assay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global ELISpot and FluoroSpot Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton, Dickinson and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. U-CyTech BV
  • 15.3. Cellular Technology Limited
  • 15.4. Mabtech AB
  • 15.5. Abcam Limited
  • 15.6. AID AUTOIMMUN DIAGNOSTIKA GMBH
  • 15.7. Mikrogen GmbH
  • 15.8. Bio-Connect Group
  • 15.9. Oxford Immunotec USA, Inc.
  • 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer